How retroperitoneal lymph node dissection affects urination and sexual function

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study that follows adult men undergoing RPLND for testicular cancer with measurements taken before surgery and at scheduled visits up to six months after the operation. Participants complete validated patient-reported outcome measures for urinary symptoms, ejaculatory and erectile function, and quality of life, and undergo non-invasive tests including uroflowmetry and post-void residual ultrasound. The design pairs subjective questionnaires with objective flow and volume measurements to characterize the timing and magnitude of functional changes after RPLND. Data will be used to describe typical recovery patterns and identify factors associated with worse urinary or sexual outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND)

Exclusion Criteria:

* History of RPLND
* Lack of consent

Where it's running

• Jagiellonian University Medical College
  Krakow, Malopolska, Poland Recruiting

Study contacts

• Principal investigator: Anna K. Czech, M.D. — Jagiellonian University
• Study coordinator: Anna K. Czech, M.D., Ph.D.
• Email: aka.czech@uj.edu.pl
• Phone: +48124002500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer

  This study will test whether primary RPLND (surgery) instead of standard chemotherapy leads to fewer side effects and better quality of life for men 18 and older with good‑prognosis metastatic testicular cancer.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Göteborg · NCT07498959

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• Primary retroperitoneal lymph node dissection for seminoma with limited retroperitoneal lymph node spread

  This trial will try surgery (retroperitoneal lymph node dissection) to treat men with pure seminoma who have one or two small (≤3 cm) retroperitoneal lymph node metastases and normal tumor markers.

  Recruiting Phase 2 Western University, Canada · London, Ontario · NCT06932458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.